Send to:

Choose Destination
See comment in PubMed Commons below
Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8.

Challenges and recommendations for early identification of metastatic disease in prostate cancer.

Author information

  • 1University of Colorado, Denver-Aurora, CO. Electronic address:
  • 2Icahn School of Medicine at Mount Sinai, New York, NY.
  • 3Fred Hutchinson Cancer Research Center, Seattle, WA.
  • 4University of Colorado School of Medicine, Denver, CO.
  • 5Durham VA and Duke University, Durham, NC.
  • 6Memorial Sloan-Kettering Cancer Center, New York, NY.
  • 7Thomas Jefferson University, Philadelphia, PA.
  • 8Oncology Consortium, Scottsdale, AZ.
  • 9Medical University of South Carolina, Charleston, SC.
  • 10Lancaster Urology, Lancaster, PA.
  • 11Carolina Urologic Research Center, Myrtle Beach, SC.
  • 12Yale University Cancer Center, New Haven, CT.


Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.

Copyright © 2014 Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk